Less Animal, More Signal: What NAMs Mean for Preclinical Neuroscience Instruments

In April 2026, the FDA reported that it had met the first-year goals of its animal-testing phase-out. Earlier this month (June 2026), the European Commission adopted its own roadmap to phase out animal testing in chemical safety assessments, including for pharmaceuticals, building on the REACH framework. Both are signals that New Approach Methodologies (NAMs) are moving from policy towards practice.

The FDA’s first-year goals were largely infrastructure and guidance: a permanent tool-qualification pathway, an NIH partnership, a database clarifying which alternatives the agency will accept, and draft guidance loosening nonhuman-primate requirements for monoclonal antibodies. Now, over a year after the FDA policy shift, the question is no longer whether these human-relevant methods are accepted in preclinical research, but which techniques the work now uses, and where animal models persist.

Neuroscience is one area where the case for human-relevant models is strongest, though it is not where the relevant NAMs are furthest along. Liver and cardiac toxicology currently lead on NAMs regulatory adoption; the FDA has accepted a liver-chip into its ISTAND qualification program for drug-induced liver injury, and cardiac microtissue platforms are being evaluated for regulatory use in cardiotoxicity screening. Oncology and immunology are moving quickly behind them, but that momentum is more on the strength of draft guidance and pipeline interest than qualified platforms. Immunology and oncology are both systemic, not single-organ specialties, so the applicable NAMs will require greater complexity and interconnectivity than current commercialized chip formats offer.

Regulators already moved relatively early on at least one neuro-specific front: the OECD’s 2023 guidance on a developmental neurotoxicity in vitro battery replaced a single animal study with human-cell assays for endpoints such as neurite outgrowth and network formation. Species differ sharply in traits like seizure susceptibility, and several mechanisms that trigger seizures in humans translate poorly to common lab animals, so the predictive gap is particularly wide in neuroscience. Human-derived NAMs offer a more direct, early-stage line to the biology in question, because the material under study is human rather than a cross-species stand-in, which matters most for neural mechanism, development, and toxicity.

In vitro screens using human-derived NAMs are likely to replace some early-stage animal work. Mice, rats, non-human primates and other animal models still carry integrative and historical neuroscience knowledge spanning genetics, physiology, and behavior, and they are not going away, especially in later-stage drug testing. Advances in organ-on-chip may extend the approach further, for instance into gut-brain and neuroimmune configurations where compartmental complexity is the point, but such co-cultures remain emerging infrastructure. Where the question turns to the whole organism, the intact central (CNS) or peripheral nervous system (PNS), or sensory and pain pathways, NAM relevance falls off and demand for in vivo models persists. The near-term reality remains a hybrid workflow.

Two-dimensional cultures, 3D neural systems, and organoids now allow direct study of neurodevelopment, synaptic function, and disease mechanism in human cells, precisely where animal models are least predictive. The growth case for the 3D cell culture market itself, the organoids, media, and cultureware, is covered in an earlier SDi blog (The Regulatory Tailwind Driving 3D Cell Culture’s Next Growth Phase). The value of a brain organoid or an iPSC-derived neural culture lies in emergent network behavior, not just tissue architecture, so the neuroscience instrument revenue lands not only in the culture itself but in the readout and characterization layers around it.

Electrophysiology methods represent some of the most important readouts in neuroscience R&D: function is the proof of human relevance, and in neuroscience, function often means electrical activity. However, not every subtechnique within electrophysiology will benefit from this regulatory shift equally. The shift favors more use of in vitro, higher-throughput, more commercialized formats for analyzing human cultured cells, while decreasing some reliance on ex vivo electrode work and custom rigs that have historically defined the field. Multi-electrode arrays (MEA), including high-density CMOS and 3D formats, are moving from a supporting technique to a core readout layer, and can be integrated with cell culture and differentiation. The commercial MEA system vendor base is concentrated in Axion BioSystems (Maestro), MaxWell Biosystems (MaxOne and MaxTwo), and Harvard Bioscience’s Multi Channel Systems. MEA culture plates and chips drive recurring revenue alongside instrument sales.

Automated patch clamp is also used in electrophysiology studies, particularly ion-channel studies and related drug screening and toxicity testing. It relies on samples consisting of living, suspended cells that are grown in vitro or harvested from animals or primary tissue cultures. Automated patch clamp systems are led by Nanion and Sophion, and, unlike manual patch clamp, have potential for high-throughput use in NAM workflows. However, signals from freshly harvested ex vivo tissue, differentiated stem cells, or primary cultures may still be required for some studies, and manual patch clamp will persist for essential tests and R&D involving intact tissue preparations and circuit-level signaling physiology (CNS or PNS).

Other life science methods, including sequencing, flow cytometry, and spatial multi-omics, help establish what a model is and which cell types or neuroinflammatory states it contains. High-content confocal imaging built for thick 3D samples, such as Revvity’s Opera Phenix and Molecular Devices’ ImageXpress Confocal HT.ai, doubles as an indirect functional readout tool through calcium imaging, while continuous in-incubator systems like Sartorius’s Incucyte track organoid growth and co-culture behavior label-free over weeks and can be used in parallel to or preceding other assays.

NAMs are not equally relevant everywhere but where they are strongest, in mechanism, function, development, and neurotoxicity, they are becoming the organizing logic of the workflow. The global regulatory shift favoring NAMs also moves demand within institutions, away from the in vivo imaging and animal-facility spend that has long anchored behavioral neuroscience, and toward the bench, a different buyer with a different procurement cycle. The open question is no longer whether NAMs matter for neuroscience instrumentation; it is which categories will scale fastest, and how much durable revenue sits in instruments themselves versus the consumables and reagents the readouts run on.